Skip to main content
SpringerLink
Log in

A comparative study of two intensified pulse cyclophosphamide remission-inducing regimens for diffuse proliferative lupus nephritis: an Egyptian experience

  • Original Article
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Introduction

Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE) that is usually treated with an extended course of intravenous (IV) cyclophosphamide (CYC). Given the side effects of this regimen, we evaluated the short-term efficacy and toxicity of a course of low-dose remission-inducing IV CYC followed by azathioprine (AZA) in a prospective controlled study among Egyptian patients with severe LN.

Patients and methods

In this single center, prospective clinical trial, we assigned 46 SLE patients with diffuse proliferative glomerulonephritis to either a high-dose (a maximum of 1 g/dose) of IV CYC (HD-CYC) for six monthly pulses followed by two quarterly pulses or a fixed low-dose (500 mg/dose) of IV CYC (LD-CYC) for six fortnightly pulses with a cumulative dose of 3 g. Each regimen was followed by AZA.

The objective

To compare between efficacy, potential toxicity and outcome of parenteral LD-CYC versus HD-CYC therapy for severe LN.

Results

Twenty patients (2 male and 18 female) received fortnightly fixed LD-CYC while 26 (5 male and 21 female) received monthly HD-CYC therapy. At the end of the study (1 year after starting therapy), there was no difference either in patients’ or in renal survival in both groups. Significant improvement of disease activity (SLE disease activity index) as well as rise of serum albumin was noticed with both regimens. Renal relapse was observed in 11.5% of HD-CYC patients and in none of the LD-CYC therapy patients. Treatment failure was seen in 5% and 3.4% (P = NS) of LD-CYC and HD-CYC patients, respectively. Infection (pneumonia and cellulitis) occurred in five patients in the LD-CYC group and four patients of HD-CYC; again this difference was not statistically significant.

Conclusion

A remission-inducing regimen of LD-CYC (cumulative dose 3 g) followed by AZA for SLE patients with proliferative LN achieves clinical results comparable to those obtained with HD-CYC without serious infection in both regimens.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ferrantelli A, Bono L, Tortorici C, Termini R, Giammarresi C, Rotolo U (2005) Treatment of lupus nephritis. G Ital Nefrol 22:S27–S33

    PubMed  Google Scholar 

  2. Tahir H, Isenberg DA (2005) Novel therapies in lupus nephritis. Lupus 14:77–82

    Article  PubMed  CAS  Google Scholar 

  3. Flanc RS, Roberts MA, Strippoli GF, Chadban SJ, Kerr PG, Atkins RC (2004) Treatment for lupus nephritis. Cochrane Database Syst Rev (1):CD002922

  4. Ponticelli C (1997) Treatment of lupus nephritis—the advantages of a flexible approach. Nephrol Dial Transplant 12:2057–2059

    Article  PubMed  CAS  Google Scholar 

  5. Appel GB, Cohen DJ, Pirani CL, Meltzer JI, Estes D (1987) Long-term follow-up of patients with lupus nephritis: a study based on the classification of the World Health Organization. Am J Med 83:877–885

    Article  PubMed  CAS  Google Scholar 

  6. Boumpas DT, Austin HA III, Vaughn EM, et al (1992) Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340:741–745

    Article  PubMed  CAS  Google Scholar 

  7. Lehman TJ, Onel K (2000) Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus. J Pediatr 136(2):243–247

    Article  PubMed  CAS  Google Scholar 

  8. Dooley MA, Hogan S, Jennette C, Falk R (1997) Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular disease collaborative network. Kidney Int 51:1188–1195

    Article  PubMed  CAS  Google Scholar 

  9. Bono L, Cameron JS, Hicks JA (1999) The very long-term prognosis and complications of lupus nephritis and its treatment. QJM 92:211–218

    Article  PubMed  CAS  Google Scholar 

  10. Urowitz MB (1993) Is “aggressive” therapy necessary for systemic lupus erythematosus? Rheum Dis Clin North Am 19:263–270

    PubMed  CAS  Google Scholar 

  11. Bansal VK, Beto JA (1997) Treatment of lupus nephritis: a meta-analysis of clinical trials. Am J Kidney Dis 29:193–199

    Article  PubMed  CAS  Google Scholar 

  12. Boumpas DT, Austin HA III, Vaughan EM, Yarboro CH, Klippel JH, Balow JE (1993) Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 119:366–369

    PubMed  CAS  Google Scholar 

  13. Gourley MF, Austin HA III, Scott D, et al (1996) Methylprednisolone and cyclophosphamide alone or in combination in patients with lupus nephritis: a randomized controlled trial. Ann Intern Med 125:549–557

    PubMed  CAS  Google Scholar 

  14. D’Cruz D, Cuadrado MJ, Mujic F, Tungekar MF, Taub N, LloydM, et al (1997) Immunosuppressive therapy in lupus nephritis. Clin Exp Rheumatol 15:275–282

    PubMed  CAS  Google Scholar 

  15. McCune WJ (2005) Mycophenolate mofetil for lupus nephritis. N Engl J Med 353:2282–2284

    Article  PubMed  CAS  Google Scholar 

  16. Ponticelli C (1997) Treatment of lupus nephritis-the advantages of a flexible approach. Nephrol Dial Transplant 12:2057–2059

    Article  PubMed  CAS  Google Scholar 

  17. Wright JT Jr, Agodoa L, Contreras G, et al (2002) Successful blood pressure control in the african american study of kidney disease and hypertension. Arch Intern Med 162: 1636–1643

    Article  PubMed  Google Scholar 

  18. Peterson JC, Adler S, Bukart JM, Greene T, Hebert LA, et al (1995) For the Modification of Diet in Renal Disease (MDRD) study group. Blood pressure control, proteinuria and the progression of renal disease. Ann Intern Med 123:754–762

    PubMed  CAS  Google Scholar 

  19. Austin HA 3rd, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, Decker JL (1986) Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 14:614–619

    Article  Google Scholar 

  20. Steinberg AD, Steinberg SC (1991) Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone alone. Arthritis Rheum 34:945–950

    Article  PubMed  CAS  Google Scholar 

  21. Lehman TJA, Sherry DD, Wagner-Weiner L, McCurdy DK, Emery HM, Magilavy DB, et al (1989) Intermittent intravenous cyclophosphamide for lupus nephritis. J Pediatr 114:1055–1060

    Article  PubMed  CAS  Google Scholar 

  22. Petri M, Jones R, Brodsky R (2003) High dose cylcophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum 48:166–173

    Article  PubMed  CAS  Google Scholar 

  23. Houssiau FA, D’Cruz DP, Haga H-J, Hughes GRV (1991) Short course of weekly low-dose intravenous pulse cyclophosphamide in the treatment of lupus nephritis: a preliminary study. Lupus 1:1–5

    Article  Google Scholar 

  24. Mok CC, Ying KY, Tang S, Leung CY, Lee KW, Ng WL, Wong RW, Lau CS (2004) Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum 50:2559–2568

    Article  PubMed  CAS  Google Scholar 

  25. Flanc RS, Roberts MA, Strippoli GF, Chadban SJ, Kerr PG, Atkins RC (2004) Treatment for lupus nephritis. Cochrane Database Syst Rev (1):CD002922

  26. Williams W, Bhagwandass A, Sargeant LA, Shah D (2003) Severity of systemic lupus erythematosus with diffuse proliferative glomerulonephritis and the ineffectiveness of standard pulse intravenous cyclophosphamide therapy in Jamaican patients. Lupus 12:640–645

    Article  PubMed  CAS  Google Scholar 

  27. Kelly JA, Moser KL, Harley JB (2002) The genetics of systemic lupus erythematosus: putting the pieces together. Genes Immun 3(Suppl):S71–S85

    Article  PubMed  CAS  Google Scholar 

  28. Petri M (2004) Cyclophosphamide: new approaches for systemic lupus erythematosus. Lupus 13:336–371

    Google Scholar 

  29. Grootscholten C, Ligtenberg G, Hagen EC, van den Wall Bake AW, de Glas-Vos JW, Bijl M, et al (2006) Dutch working party on systemic lupus erythematosus. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 70:732–742

    Article  PubMed  CAS  Google Scholar 

  30. Mok CC, Ho CT, Chan KW, Lau CS, Wong RW (2002) Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum 46:1003–1013

    Article  PubMed  CAS  Google Scholar 

  31. Sidiropoulos PI, Kritikos HD, Boumpas DT (2005) Lupus nephritis flares. Lupus 14:49–52

    Article  PubMed  CAS  Google Scholar 

  32. Tangnararatchakit K, Tapaneya-Olarn C, Tapaneya-Olarn W (1999) The efficacy of intravenous pulse cyclophosphamide in the treatment of severe lupus nephritis in children. J Med Assoc Thai 82:S104–S110

    PubMed  Google Scholar 

  33. Kang I, Park SH (2003) Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumatol 15:528–534

    Article  PubMed  CAS  Google Scholar 

  34. Calguneri M, Ozbalkan Z, Ozturk MA, Apras S, Ertenli AI, Kiraz S (2006) Intensified, intermittent, low-dose intravenous cyclophosphamide together with oral alternate-day steroid therapy in lupus nephritis (long-term outcome). Clin Rheumatol 25:782–788

    Article  PubMed  Google Scholar 

  35. Pryor BD, Bologna SG, Kahl LE (1996) Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Nephron 74:313–317

    Article  Google Scholar 

  36. D’Cruz D, Cuadrado MJ, Mujic F, Tungekar MF, Taub N, Lloyd M, et al (1997) Immunosuppressive therapy in lupus nephritis. Clin Exp Rheumatol 15:275–282

    PubMed  CAS  Google Scholar 

  37. Mok CC, Ying KY, Ng WL, Lee KW, To CH, Lau CS, et al (2006) Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med 119(355):e25–e33

    PubMed  Google Scholar 

  38. Manger K, Wildt L, Kalden JR, Manger B (2006) Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study. Autoimmun Rev 5:269–272

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgement

We are very grateful to Michelle Chambers, Psychological Assistant, HMP Littlehey, Huntingdon, UK, for the linguistic revision of the manuscript.

Author information

Authors and Affiliations

  1. Nephrology Department, Urology and Nephrology center, University of Mansoura, Mansoura, Dakhlia, 35555, Egypt

    Alaa Sabry, Tarek Medhat, Hussein Sheashaa, Khaled Mahmoud & Amr El-Huseini

  2. Department of Internal Medicine, University of Mansoura, Al Ghomhoria street, Mansoura, Dakhlia, 35555, Egypt

    Alaa Sabry

  3. Faculty of Medicine, Menuofiya University, Menuofiya, Egypt

    Hamdy Abo-Zenah

Authors
  1. Alaa Sabry
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hamdy Abo-Zenah
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tarek Medhat
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hussein Sheashaa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Khaled Mahmoud
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Amr El-Huseini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alaa Sabry.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sabry, A., Abo-Zenah, H., Medhat, T. et al. A comparative study of two intensified pulse cyclophosphamide remission-inducing regimens for diffuse proliferative lupus nephritis: an Egyptian experience. Int Urol Nephrol 41, 153–161 (2009). https://doi.org/10.1007/s11255-007-9325-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-007-9325-4

Keywords

Search

Navigation